Market Research Logo

Anti-epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region - Global Industry Insights, Trends, and Forecast, 2017-25

Anti-epileptic Drugs for Pediatrics Market by Drug Type (1st generation, 2nd generation, and 3rd generation), and Region - Global Industry Insights, Trends, and Forecast, 2017-25

Anti-epileptics drugs for pediatrics treatment are expected to experience visible shifts in terms of demand and adoption owing to factors such as rise in global prevalence of epilepsy, increasing healthcare spending and emergence of efficacious newer anti-epileptic drugs. Furthermore, co-morbidities associated with epilepsy such as depression and anxiety are on rise and major players are investing in the research and awareness programs for reduction of these co-morbidities along with epilepsy. For instance, Sanofi, S.A. invests major amounts into awareness programs in regions with emerging economies such as Latin America, Africa, and Asia Pacific. The company offers products with price adjustments in these regions to increase the access to these treatments. The investments by major players in the pipeline over the past few years have shown positive results in terms of product launches such as Vimpat drug approvals in Europe and Japan in the treatment of partial onset seizures for UCB Pharma in 2016.
Market Dynamics
Major market players are focusing on providing viable treatment options in patients suffering from refractory epilepsy or drug resistant epilepsy. The add-on or adjunctive therapies designed by market players offer significant positive results with relatively less side effects. This, in turn, is expected to boost the market growth rate for anti-epileptic drugs. Some notable drugs in the pipeline such as Lyrica (Pregabalin), are showing potential therapeutic effects with fewer drug interactions, improved side effect profiles, and enhanced overall safety. This addresses a major need in the AED market, since most of the older treatments such as carbamazepine, valproate, and phenytoin, although effective, have very poor safety profiles and are not well-tolerated by pediatric patients.
Market Taxonomy
This report segments the global Anti-Epileptic Drugs for Pediatrics Market on the basis of drug type and region. On the basis of drug type, the global Anti-Epileptic Drugs for Pediatrics Market is segmented into 1stgeneration, 2nd generation, and 3rd generation.
Key features of the study:

  • This report provides in-depth analysis of Anti-Epileptic Drugs for Pediatrics Market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2016 – 2025), considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Anti-Epileptic Drugs for Pediatrics Market on the basis of the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Mylan N.V.*, Cephalon, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc., Sanofi S.A., UCB Pharma Limited, Sunovion Pharmaceuticals Limited, Valeant Pharmaceuticals International, Inc., Zogenix, GW Pharmaceuticals, Insys, and Zynerba.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global Anti-Epileptic Drugs for Pediatrics Market report caters to various stakeholders in this industry, including investors, suppliers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Anti-Epileptic Drugs for Pediatrics Market
Detailed Segmentation:
  • Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Global Anti-Epileptic Drugs for Pediatrics Market, By Geography:
  • North America
  • U.S.
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Canada
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Europe
  • U.K.
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Germany
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Italy
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • France
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Russia
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Rest of Europe
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Asia-Pacific
  • China
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • India
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Japan
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • ASEAN
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Australia
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • South Korea
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Rest of Asia Pacific
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Latin America
  • Brazil
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Mexico
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Rest of Latin America
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Middle East
  • GCC
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Israel
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Africa
  • North Africa
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Central Africa
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • South Africa
  • By Drug Type:
  • 1st Generation
  • 2nd Generation
  • 3rd Generation
  • Competitive Landscape
  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
  • Mylan N.V.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Cephalon, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • GlaxoSmithKline plc
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Janssen Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Novartis AG
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Sanofi S.A.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • UCB Pharma Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Sunovion Pharmaceuticals Limited
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Valeant Pharmaceuticals International, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Zogenix
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • GW Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Insys
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Zynerba
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Future Plans
  • Analyst Views
  • Section
  • References
  • Research Methodology
  • About Us and Sales Contact
*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025”.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Supply Side Drivers
Demand Side Drivers
Economic Drivers
Restraints
Market Opportunities
Epidemiology
Merger and Acquisitions
PEST Analysis
Pipeline Drug Analysis
Recently Launched Drug Analysis
Cost Tier Down Analysis
4. Global Anti-Epileptic Pediatric Drugs Market, By Drug Type, 2017 - 2025, (US$ Million)
Introduction
Market Share Analysis, 2016 and 2025 (%)
Y-o-Y Growth Analysis, 2017 - 2025
Segment Trends
1st Generation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
2nd Generation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
3rd Generation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (USD Million)
5. Global Anti-Epileptic Pediatric Drugs Market, By Regions, 2017 - 2025, (US$ Million)
Introduction
Market Share Analysis, By Region, 2016 and 2025 (%)
Y-o-Y Growth Analysis, For Regions, 2017 - 2025
North America
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
U.S.
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Canada
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Europe
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
U.K.
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Germany
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Italy
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
France
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Russia
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Others
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Asia Pacific
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
China
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
India
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Japan
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
ASEAN
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Australia
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
South Korea
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Others
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Latin America
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
Brazil
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Mexico
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Others
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Africa
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
Northern Africa
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Central Africa
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
South Africa
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Middle East
Market Share Analysis, By Country, 2016 and 2025 (%)
Y-o-Y Growth Analysis, By Country, 2017 - 2025
GCC Countries
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Israel
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
Others
Country Trends
Market Size and Forecast, By Drug Type, 2017 - 2025, (US$ Million)
6. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Company Profiles
Mylan N.V.
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Cephalon, Inc.
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
GlaxoSmithKline plc
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Janssen Pharmaceuticals
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Novartis AG
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Pfizer, Inc.
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Sanofi S.A.
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
UCB Pharma Limited
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Sunovion Pharmaceuticals Limited
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Valeant Pharmaceuticals International, Inc.
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Zogenix
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
GW Pharmaceuticals
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Insys
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Zynerba
Company Overview
Drug Type Portfolio
Financial Performance
Recent Developments/Updates
Future Plans
Analyst Views
7. Section
References
Research Methodology
About Us and Sales Contact
*Browse 23 market data tables and 43 figures on "Anti-Epileptic Pediatric Drugs Market - Global forecast to 2025”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report